Target ALS, AFTD Award $5M to Support Research Projects

Target ALS, AFTD Award $5M to Support Research Projects
4.6
(5)

Grant awards totaling $5 million will support six academic-industry projects into potential biomarkers and treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD), Target ALS and the Association for Frontotemporal Degeneration (AFTD) announced.

The two groups joined to support this collaborative work as ALS and FTD, the most common dementia of people under age 60, share genetic causes and biological mechanisms.

Disease biomarkers are key tools for guiding therapy development and mapping disease progression, with their discovery informing treatments for ills that range from cardiovascular disorders to cancer.

Target ALS and the ALS Association recently joined to financially support two research projects focused on the development of new tests to assess TDP-43’s potential as an ALS biomarker.

“Funding collaborative efforts has led to the most promising research coming out of our Innovation Ecosystem, the model we created in 2013 to bring the best minds together and achieve impactful results,” Manish Raisinghani, PhD, Target ALS CEO, said in a press release. “Partnering with AFTD has been an incredible step forward in that commitment, now reaching a critical milestone.”

Innovation Ecosystem brings together scientists, funding, critical tools, and resources to speed the discovery and development of breakthrough ALS therapies.

Those with the newly funded research teams will have access to Innovation Ecosystem tools and resources including, human biosamples, genomic datasets, and stem cells.

FTD and ALS overlap clinically, imaging-wise, and pathologically. For example, it’s been discovered that mutation of the C9orf72 gene is the most common genetic cause of both disorders. In ALS, the mutations account for up to 40% of familial ALS cases.

The $5 million will be shared among these groups and projects:

“We’re proud to join Target ALS in announcing funding for these crucial funding efforts,” said Susan L-J Dickinson, the AFTD’s CEO. “With the challenges that the COVID-19 pandemic is adding for the families we serve, we want them to know that we are working as hard as ever to bring momentum for a day when treatments can halt FTD and ALS in their tracks.”

Visit this site for more information about the Target ALS and AFTD collaboration.

Target ALS funds collaborative research consortia that pursue novel approaches in ALS treatment discovery and development. The AFTD seeks to improve the quality of life of people affected by FTD, and drive research toward a cure.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 0
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Radicava support program
  • ALS mattress, sleep
  • ALS Awareness Month

How useful was this post?

Click on a star to rate it!

Average rating 4.6 / 5. Vote count: 5

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?